Terapevticheskie vozmozhnosti metformina pri vosstanovlenii fertil'nosti u patsientok s sindromom polikistoznykh yaichnikov
https://doi.org/10.14341/brh20083-413-24
Abstract
СПКя – клинический синдром, характерными клиническими признаками которого являются гиперандрогения, нарушение овуляции и увеличение объема яичников за счет множественных фолликулов по периферии. Дефиниция СПКя остается до сих пор дискуссионным вопросом – клинические признаки синдрома неспецифичны и довольно распространены в популяции среди практически здоровых женщин. СПКя фактически является гетерогенным состоянием, поэтому обсуждение диагностических критериев остается ключевым вопросом для понимания синдрома. К настоящему времени были предложены и приняты два варианта диагностических критериев. В апреле 1990 г – критерии Национального Института Здоровья (NIH) и Национального Института Здоровья ребенка и Развития человека (NICHD) США [1]. После длительного обсуждения в Роттердаме в мае 2003 г приняты действующие в настоящее время диагностические критерии Европейского Общества Репродукции Человека и Эмбриологии (ESHRE) и Американского Общества Репродуктивной Медицины (ASRM) [2]. Роттердамские критерии значительно расширили количество клинических фенотипов СПКя.
References
1. Zawadzki J.K., Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A., Givens J.R., Haseltine F.P., Merriam G.R., eds. PCOS. Boston: Blackwell. 1992;337– 384.
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS. Fertil Steril 2004;81:19–25.
3. Polson D.W., Adams J., Wadsworth J., Franks S. Polycystic ovaries — a common finding in normal women. Lancet 1988;1:870–872.
4. Azziz R., Carmina E., Dewailly D. et al. Androgen Excess Society. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. JCE&M 2006; 91:4237–4245.
5. Adams J.M., Taylor A.E., Crowley W.F. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. JCE&M 2004; 89:4343–4350.
6. Apridonidze T., Essah P.A., Iuorno M.J., Nestler J.E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. JCE&M 2005;90:1929–1935.
7. Kahsar-Miller M.D., Nixon C., Boots L.R. et al. Prevalence of PCOS in first-degree relatives of patients with PCOS. Fertil Steril 2001;75:53– 58.
8. Hague W.M., Adams J., Reeders S.T. Familial polycystic ovaries: a genetic disease? 1988 Clin Endocrinol (Oxf) 29:593-605 25
9. Синдром поликистозных яичников под редакцией И.И. Дедова, Г.А. Мельниченко. МИА. Москва. 2007.
10. Azziz R., Woods K.S., Reyna R., Key T.J. The prevalence and features of the PCOS in an unselected population. JCE&M 2004;89:2745–2749.
11. Dunaif A. Insulin resistance and the PCOS: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800.
12. Legro R.S., Castracane V.D., Kauffman R.P. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004 59:141–154
13. Lord J.M., Flight I.H., Norman R.J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for PCOS. 2003. Cochrane Database Syst Rev CD003053.
14. Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of PCOS -a reappraisal. Nat Clin Pract Endocrinol Metab 2008;4:272–283.
15. Diamanti-Kandarakis E. Insulin sensitizers targeting metabolic and reproductive consequences of PCOS. In: Dunaif A. Polycystic ovary syndrome current controversies: from ovary to pancreas. USA. Humana Press. 2008;199–216.
16. Velazquez E.M., Mendoza S., Hamer T. Metformin therapy in PCOS reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabol 1994;43:647–654.
17. Salley K.E., Wickham E.P., Cheang K.I. Position Statement: Glucose intolerance in polycystic ovary syndrome a position statement of the Androgen Excess Society. JCE&M 2007;92:4546–4556.
18. Polycystic Ovary Syndrome Writing Committee American Association of Clinical Endocrinologists position statements on metabolic and cardiovascular consequences of PCOS. Endocr Pract 2005;11:126– 134.
19. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to PCOS. Fertil Steril 2008;89:505–522.
20. Holte J., Bergh T., Berne C. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with PCOS. JCE&M 1995;80:2586–2593.
21. Skov V., Glintborg D., Knudsen S. Reduced expression of nuclearencoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with PCOS. Diabetes 2007;56:2349– 2355.
22. Rosenfield R.L., Barnes R.B., Cara J.F. Dysregulation of cytochrome P450c 17 alpha as the cause of PCOS. Fertil Steril 1990;53:785–791.
23. Hsueh A.J., Billig H., Tsafriri A. Ovarian follicle atresia: a hormonally controlled apoptotic process. Endocr Rev 1994;15:707–724.
24. Dunn C.J., Peters D.H. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49:721–49.
25. Vanky E., Zahlsen K., Spigset O., Carlsen S.M. Placental passage of metformin in women with PCOS. Fertil Steril 2005;83:1575–1578.
26. Elliott B.D., Langer O., Schuessling F. Human placental glucose uptake and transport are not altered by the oral antihyperglycemic agent metformin. Am J Obstet Gynecol 1997;176:527–530.
27. Glueck C.J., Wang P. Metformin before and during pregnancy and lactation in PCOS. Expert Opin Drug Saf 2007;6:191–198.
28. Dell’aglio D.M., Perino L.J., Todino J.D. Metformin overdose with a resultant serum pH of 6.59: survival without sequalae. J Emerg Med 2008; 14: 11.
29. Zain M.M., Jamaluddin R., Ibrahim A. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with PCOS: a randomized controlled trial. Fertil Steril 2008;91: 514–521.
30. Palomba S., Orio F. Jr, Falbo A. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with PCOS. JCE&M 2005; 90: 4068–4074.
31. Legro R.S., Barnhart H.X., Schlaff W.D. et al. Cooperative Multicenter Reproductive Medicine Network Clomiphene, metformin, or both for infertility in the PCOS. N Engl J Med 2007;356:551–566.
32. Ibanez L., Valls C., Potau N. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. JCE&M 2000;85:3526–353.
33. Palomba S., Falbo A., Russo T. Insulin sensitivity after metformin suspension in normal-weight women with PCOS. J Clin Endocrinol Metab 2007;92:3128–3135.
34. Rowan J.A., Hague W.M., Gao W. MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008;358:2003–2015.
35. Koren G., Gilbert C., Valois M. Metformin use during the first trimester of pregnancy. Is it safe? Can Fam Physician 2006;52:171–172.
36. Gilbert C., Valois M., Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 2006;86:658–663.
37. Thatcher S.S., Jackson E.M. Pregnancy outcome in infertile patients with PCOS who were treated with metformin. Fertil Steril 2006;85:1002– 1009.
38. Bolton S., Cleary B., Walsh J. Continuation of metformin in the first trimester of women with PCOS is not associated with increased perinatal morbidity. Eur J Pediatr 2008;90:727–730.
39. Tan S., Hahn S., Benson S. Metformin improves PCOS symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 2007;157:669–676.
40. Marcondes J.A., Yamashita S.A., Maciel G.A. Metformin in normalweight hirsute women with PCOS with normal insulin sensitivity. Gynecol Endocrinol 2007;23:273–278.
41. Maciel G.A., Soares Junior J.M. Nonobese women with PCOS respond better than obese women to treatment with metformin. Fertil Steril 2004;81:355–360.
42. Legro R.S., Barnhart H.X., Schlaff W.D. Reproductive Medicine Network Ovulatory response to treatment of PCOS is associated with a polymorphism in the STK11 gene. JCE&M 2008;93:792–800.
43. Harborne L.R., Sattar N., Norman J.E. Metformin and weight loss in obese women with PCOS: comparison of doses. JCE&M 2005;90:4593– 4598.
44. Bruno R.V., de Avila M.A., Neves F.B. Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of PCOS and their effect on body mass index and waist circumference. Fertil Steril 2007;88:510– 512.
45. Eisenhardt S., Schwarzmann N., Henschel V. Early effects of metformin in women with PCOS: a prospective randomized, doubleblind, placebo-controlled trial. JCE&M 2006;91:946–952.
46. Moghetti P., Castello R., Negri C. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in PCOS: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. JCE&M 2000;85:139– 146.
47. Fleming R., Hopkinson Z.E., Wallace A.M. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. JCE&M 2002;87:569–574.
48. Liu K.E., Tataryn I.V., Sagle M. Use of metformin for ovulation induction in women who have PCOS with or without evidence of insulin resistance. J Obstet Gynaecol Can 2006;28:595–599.
49. Moghetti P., Castello R., Negri C. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in PCOS: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. JCE&M 2000;85:139– 146.
50. Chang W.Y., Knochenhauer E.S., Bartolucci A.A. Phenotypic spectrum of PCOS: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 2005;83:1717–1723.
51. Moll E., Korevaar J.C., Bossuyt P.M. Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with PCOS? Hum Reprod 2008;23:1830–1834.
52. Costello M.F., Shrestha B., Eden J. Metformin versus oral contraceptive pill in PCOS: a Cochrane review. Hum Reprod 2007;22:1200–1209.
53. Pasquali R., Gambineri A., Anconetani B. PCOS The natural history of the metabolic syndrome in young women with the PCOS and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999;50:517–527.
54. Чеботникова Т.В., Мельниченко Г.А., Семичева Т.В. Принципы восстановления фертильности у больных с синдромом поликистозных яичников. Вестник репродуктивного здоровья 2008; №1-2. с.3851.
55. Costello M.F., Eden J.A. A systematic review of the reproductive system effects of metformin in patients with PCOS. Fertil Steril 2003;79:1–13.
56. Lord J.M., Flight I.H., Norman R.J. Metformin in PCOS: systematic review and meta-analysis. BMJ 2003;327:951–953.
57. Kashyap S., Wells G.A., Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with PCOS. Hum Reprod 2004; 19: 2474– 2483.
58. Creanga A.A., Bradley H.M., McCormick C. Use of metformin in PCOS: A meta-analysis. Obstet Gynecol 2008;111:959–968.
59. Palomba S., Falbo A. Metformin in therapy naive patients with PCOS. Hum Reprod Update 2008;14:193.
60. Moll E., van der Veen F., van Wely M. The role of metformin in PCOS: a systematic review. Hum Reprod Update 2007;13:527–537.
61. Moll E., Bossuyt P.M., Korevaar J.C. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed PCOS: randomised double blind clinical trial. BMJ 2006; 332: 1485.
62. Ng E.H., Wat N.M., Ho P.C. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 2001; 16: 1625–1631.
63. Palomba S., Orio F. Jr, Nardo L.G. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with PCOS: a prospective parallel randomized double-blind placebocontrolled trial. JCE&M 2004; 89: 4801–4809.
64. Kocak I., Ustun C. Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with PCOS following laparoscopic ovarian drilling. J Obstet Gynaecol Res 2006; 32: 292–298.
65. Siebert T.I., Kruger T.F., Steyn D.W., Nosarka S. Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with PCOS? A structured literature review. Fertil Steril 2006; 86: 1432–1437.
66. Palomba S., Orio F. Jr, Falbo A. Laparoscopic ovarian diathermy versus metformin plus clomiphene citrate administration as secondline strategy for infertile anovulatory patients with PCOS: a randomized controlled trial. Hum Reprod 2008; 22: 1532–1535.
67. George S.S., George K., Irwin C. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women PCOS a randomized, controlled trial. Hum Reprod 2003; 18: 299–304.
68. Nestler J.E., Jakubowicz D.J., Evans W.S. Effects of metformin on spontaneous and clomiphene-induced ovulation in the PCOS N Engl J Med 1998; 338: 1876–1880.
69. Khorram O., Helliwell J.P., Katz S. Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with PCOS. Fertil Steril 2006; 85:1448–1451.
70. Sturrock N.D., Lannon B., Fay T.N. Metformin does not enhance ovulation induction in clomiphene resistant PCOS in clinical practice. Br J Clin Pharmacol 2002; 53: 469–473.
71. Hwu Y.M., Lin S.Y., Huang W.Y. Ultra-short metformin pretreatment for clomiphene citrate-resistant PCOS. Int J Gynaecol Obstet 2005; 90: 39–43.
72. Palomba S., Orio F. Jr, Zullo F. What is the best first-step therapeutic approach in treating anovulatory infertility in patients with PCOS? Questions that are still unanswered. Gynecol Endocrinol 2007; 23: 245– 247.
73. Palomba S., Orio F. Jr., Falbo A. Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with PCOS. Clin Endocrinol 2005; 63: 631–635.
74. Costello M.F., Chapman M., Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin coadministration during gonadotrophin ovulation induction or IVF in women with PCOS. Hum Reprod 2006; 21: 1387–1399.
75. Vandermolen D.T., Ratts V.S., Evans W.S. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with PCOS who are resistant to clomiphene citrate alone. Fertil Steril 2001; 75: 310–315.
Review
For citations:
Chebotnikova T.V., Semicheva T.V. Terapevticheskie vozmozhnosti metformina pri vosstanovlenii fertil'nosti u patsientok s sindromom polikistoznykh yaichnikov. Bulletin of Reproductive Health. 2008;(3-4):13-24. (In Russ.) https://doi.org/10.14341/brh20083-413-24
Views:
1650
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
